[2] Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int. 2004 Jun;93(9):1177-82
[3] Prostate Cancer Triallists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 1491-1498
[4] Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic cancer. N Engl J Med1989; 321: 419-424
[5] Denis LJ, Keupprens F, Smith PH et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Uro 1998; 33: 144-151 [abstract only]
Peter Edwards, director de Casodex Global Brand PR, AstraZeneca, Tel.:+44-1625-232-685, Móvil: +44-7747-118-498, Peter.S.Edwards@astrazeneca.com; Rebecca Hibble, Cohn & Wolfe, Tel.: +44-207-331-5336, Móvil: +44-7813-096-161, rebecca_hibble@uk.cohnwolfe.com
